HER2 Support Group Forums - View Single Post - Amgen's motesanib (AMG-706), VEGF inhibitor in metastatic breast cance

Rich66 · 09-24-2009, 03:32 PM

From an e-mail bulletin:

6) Amgen's motesanib (AMG-706), a VEGF inhibitor looks active in metastatic breast cancer

"Motesanib in combination with P (paclitaxel) or D (docetaxel) appears to be tolerable and shows evidence of antitumor activity in pts with advanced breast cancer. Coadministration with either P or D had no major effect on motesanib PK."

I've been following this agent for a little while as it started cropping up in searches for clinical trials in multiple tumor types. It appears to target VEGF, KIT and PDGF. Poster PD-5029 is a dose finding study, so the emphasis is on adverse events and tolerability rather than efficacy, but 28-29% response rates this early are interesting at this stage. This is one agent I'll be following more closely as more results are published in the future.

09-24-2009, 03:32 PM	#1
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Amgen's motesanib (AMG-706), VEGF inhibitor in metastatic breast cance From an e-mail bulletin: 6) Amgen's motesanib (AMG-706), a VEGF inhibitor looks active in metastatic breast cancer "Motesanib in combination with P (paclitaxel) or D (docetaxel) *appears to be tolerable and shows evidence of antitumor activity in pts with advanced breast cancer. Coadministration with either P or D had no major effect on motesanib PK."* I've been following this agent for a little while as it started cropping up in searches for clinical trials in multiple tumor types. It appears to target VEGF, KIT and PDGF. Poster PD-5029 is a dose finding study, so the emphasis is on adverse events and tolerability rather than efficacy, but 28-29% response rates this early are interesting at this stage. This is one agent I'll be following more closely as more results are published in the future.